Pharmacovigilance

(213) A Clinical Pharmacist-Led Integrated Approach for The Evaluation of Drug-Related Problems Among Critically Ill Patients

(223) A Description of Acute Renal Failure Associated with Sodium Glucose Co-Transporter 2 Inhibitors Use: A Vigibase Study

(321) A Retrospective Analysis of Adverse Drug Events Leading to Hospitalization or Prolonged Hospitalization in Saudi Arabia Using the Saudi Food and Drug Authority (SFDA) Spontaneous Reporting System

(219) A Description of Nephrolitiasis Associated with Sodium Glucose Co-Transporter 2 Inhibitors Use: A Vigibase Study

(176) A National Viewpoint of Community Pharmacists of Pharmacovigilance and Adverse Drug Reaction Reporting in Saudi Arabia

(M) Association of Sacubitril/Valsartan with Hypoacusis Unveiled Through Disproportionality Analysis in US FDA Adverse Event Reporting System (FAERS)

(L) Comparative Cardiovascular Events Associated with Denosumab Vs. Zoledronate in The Elderly: A 5-Year Follow-Up Propensity Score Matching Cohort

(N) Triazole Anti-fungals Associated with Acute Pancreatitis: A Disproportionality Analysis in a Spontaneous Reporting Database

(313) An Active Surveillance of Medication Error Monitoring Programme in a Tertiary Care Teaching Hospital: A Clinical Pharmacist Approach

(209) A Systematic Process Using Robust Signal Detection and Contextualization Methods in Treescan® and E360® to Reduce False Positives in Routine Pharmacovigilance

(306) Assessing Causality in HIV-Positive Patients with Antituberculosis And/or Antiretroviral Therapy – Associated Liver Injury

(231) Adverse Effects Following Immunization (AEFI) of COVID-19 Vaccines in Two Tertiary Health Facilities in Lagos Nigeria

(314) Assessing The Pattern of Hypersensitivity Reactions Associated with Analgesics: An Ambispective Study

(183) An Examination of How Serious Infection Are Reported in Spontaneous Reports

(189) Appendicitis Associated with Pembrolizumab Use: Adverse Events- Signal Review

(320) Association Between Oral Corticosteroid Prescribing Patterns and Appropriate Fracture Preventive Care in People with Atopic Eczema in the UK

(222) Anti-NMDA Receptor Encephalitis and Vaccines

(307) Cardiovascular Adverse Events Associated with PARP Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System

(242) Are Drug Safety Measures Harmonized? A Real-World Data from Three Regulatory Authorities

(220) BBIBP-Corv Vaccine: An Analysis of Adverse Events on Health Personnel by a Peruvian Pharmacovigilance Center

(311) Community Pharmacists' Vigilance Towards OTC Medication Abuse in Saudi Arabia

(245) Benefits of Telepharmacy Services for Improving Medication Safety in Cardiovascular Diseases

(216) Bidirectional Relationship Between Urinary Retention and The Use of Antipsychotics

(167) Community Pharmacists-Reported Barriers and Facilitators for Adverse Drug Reaction Reporting; Findings of a Focus Group Study

(187) Comparative Study of Osteonecrosis of The Jaw with Bisphosphonates and Denosumab in Two Pharmacovigilance Database

(192) Conducting Observational Multi-Country Studies for Regulatory Decision Making During COVID-19 Pandemic: The Strategic Role of The Scientific Project Manager

(309) Comparison of Post-Marketing Drug Safety Surveillance Research Required by Regulators of the United States and Europe Through the Case of Dapagliflozin

(227) Comparison of Hemorrhagic Profile Amongst Direct Acting Oral Anti-Coagulants (DOACs): Risk Quantification by Using US FDA Adverse Event Reporting System (FAERS)

(319) Current Status of Spontaneous Adverse Event Reports Related to Polypharmacy in Korean Elderly Patients

(179) Descriptive Analysis of Disproportionate Medication Errors and Associated Patient-Characteristics in The Food and Drug Administration's Adverse Event Reporting System

(233) Cytomegalovirus Infection Reactivation in Multiple Myeloma Patients Administered Proteasome Inhibitor-Combination Therapy: A Disproportionality Analysis in a Spontaneous Reporting Database

(226) Determination of Predictors of Drug Related Problems Associated with Narrow Therapeutic Index Drugs

(237) Dipeptidyl Peptidase-4 Inhibitors and Acute Pancreatitis - A Systematic Review of Descriptive Studies

(207) Disproportionality Analysis for Post-Manufacturing Change Safety Monitoring of Biologics: Example of Insulin Lispro

(175) Distinguishing Patterns Associated with Statin-Related Myopathy Using Korea Adverse Event Reporting System Database: Unsupervised Machine Learning Methods

(310) Drug Use Pattern and Adverse Reactions Among Pregnant Women Accessing Care at The University College Hospital, Ibadan, Nigeria

(AF) Hypothesis-Free Screening for Carcinogenic Effects of Drugs

(AE) Use of Selective Serotonin Reuptake Inhibitors (SSRI) and Risk of Breast Cancer

(M) Development of a Tool for Visualizing Patient Journeys Using Disease Blogs on The Internet

(L) Identifying Protective Drugs for Parkinson's Disease: Large Screening of The French National Healthcare Database with Signal Detection Machine Learning Algorithms

(AA) Adverse Events of Myopathy After Comedication of Statin-Contraindicated Drugs: Case/Noncase Study Using Korea Adverse Event Reporting System (KAERS) Database, 2016-2020

(AB) Concomitant Use of Sodium-Glucose Co-Transporter 2 Inhibitors and Statins and The Risk of Myotoxicity - A Pharmacovigilance Study

(178) Drugs-Associated with Red Man Syndrome: An Integrative Approach Using Disproportionality Analysis and PHARMIP

(241) Evaluation of Published Data on Risk Minimization Measures in The Gulf Region: A Systematic Review

(243) Evaluation of Remifentanil's Safety Profile: A Multicenter Post Marketing Surveillance in Indonesia

(206) Evaluation of The Safety Information in "Fertility, Pregnancy and Lactation" Section of Product Information in Saudi Arabia

(174) Establishment and Validation of Automatic Monitoring Module for Drug-Induced Arrhythmia Based on Hospital Information System Data

(212) Factors Associated with Under-Reporting of Adverse Drug Reactions: A Systematic Review

(234) Features of Case Reports That Support Putative Causal Relationships Between Medicinal Products and Suspected Adverse Drug Reactions. Preliminary Results from a Scoping Review

(244) Flaxseed Interaction with Warfarin and Clopidogrel and The Potential Risk of Bleeding

(228) Gastrointestinal Adverse Events Associated with Hedgehog Pathway Inhibitors: A Real-World Pharmacovigilance Study

(308) Evaluating The Efficacy of Clustering Methods Applied to Adverse Event Reports

(324) Factors Associated with Compliance to The Hepatotoxicity Risk Management Guide in Primary Care Facilities in Casablanca, Morocco

(188) How Has Machine Learning Been Used in Patient Safety?

(312) Gastrointestinal Adverse Events Associated with PI3K Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System

(317) Ginkgo Biloba Interaction with Non-Steroidal Anti-Inflammatory Drugs and The Potential Risk of Bleeding

(240) Incidence Rate of Skin Cancers in Adult Patients with Atopic Dermatitis

(182) Impact of the COVID-19 Pandemic on Drug Safety Surveillance: An Analysis of The Canadian Spontaneous Reporting Database

(229) Investigating Self-Poisoning in The FDA Adverse Event Reporting System: Clinical Features and Lethal Dose Estimation

(225) Medication Related Problems Among Adult Diabetic Outpatients at a National Referral Hospital in Kenya

(184) Lopinavir Induced Hypospadias: New Signal Detection for Lopinavir by Disproportionality Analysis Using USFDA Database

(186) Medication Errors Among Patients Admitted with Cardiovascular Disorders at The Critical Care Unit of a National Referral Hospital in Kenya

(211) Non-Steroidal Anti-Inflammatory Drugs Use and Micronutrient Status

(323) Lot-Specific Monitoring of Insulin Lispro Safety Following Changes in The Purification Process

(208) Overview of Biases Affecting the Interpretation of Signals Identified in Drug Safety Surveillance Systems

(214) Patient Reported Adverse Events Following Anaesthesia: A Patient Centric Study

(315) Machine Learning to Predict Safety Signals Using Molecular Similarity and Disproportionate Reporting Rates

(239) Performance of Subgrouped Proportional Reporting Ratios in the US Food and Drug Administration (FDA) Adverse Event Reporting System

(194) Optic Neuritis Associated with PD-1 /PD-L1 Checkpoint Inhibitors: Case Series Utilizing the WHO Global Database of Individual Case Safety Reports (ICSRs)

(190) Pancreatic Carcinoma Associated with Liraglutide Use: Adverse Events- Signal Review

(172) Pembrolizumab and The Potential Risk of Cholestasis: A Review of Pharmacovigilance Data

(169) Post-Marketing Safety Profile of Cannabis Products: Signals from The FDA Adverse Event Reporting System

(177) Post-Marketing Safety Profile of Pethidine in Indonesia

(195) Exposure to Integrase-inhibitor Antiretroviral Drugs During Pregnancy and Congenital Abnormalities: A Case/Non-case Study from the International Pharmacovigilance Database Vigibase®

(215) Prevalence, Attributes, and Risk-Factors of QT-Interval Extending Drugs & Drug-Drug Interactions in Cancer Patients: A Prospective Study in a Tertiary Care Hospital

(224) Psoriatic Conditions After Lithium Exposure: French Pharmacovigilance Data

(322) Pharmacovigilance Education in Pharmacy Programs' Curricula in Saudi Arabia

(232) Purine Antimetabolites Associated with Pneumocystis Jiroveci Pneumonia: A Disproportionality Analysis in a Spontaneous Reporting Database

(238) QT Prolongation After the Combined Use of Haloperidol and Contraindicated Drugs: A Case/Non-Case Study Using Korea Adverse Event Reporting System (KAERS) Database, 2016-2020

(170) Pulmonary Related Adverse Events Associated with Bruton's Tyrosine Kinase Inhibitor: A Disproportionality Analysis in a Spontaneous Reporting Database

(185) Risk of Ischemic Stroke Among a Nationwide Cohort of Patients Receiving Antipsychotics: Role of Α1-Adrenergic and 5-HT1A Antagonism

(217) Risk of Osteoporosis Associated with HMG-CoA Reductase Inhibitors in Patients with Dyslipidemia

(181) Safety Surveillance for COVID-19 Vaccines at The National Pharmacovigilance Centre Lareb

(193) Screening and Monitoring Testing of HIV Pre-Exposure Prophylaxis Use Among Commercially Insured Patients, 2016-2019

(205) Role of Human Leukocyte Antigen in Anti-Epileptic Drugs Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Meta-Analysis

(180) Sex Differences in The Number and Type of Adverse Drug Reactions Reported for Common Cardiovascular Medications in a Cardiac Outpatient Population

(218) Safety and Effectiveness of N-Methyl-D-Aspartate (NMDA) Receptor Antagonists for Depression: A Narrative Review

(191) Soft Tissue Sarcomata in Humans at Potential Injection Sites, United States, 1975 – 2018

(318) Risk of Oligospermia with Tyrosine Kiase Inhibitors: A Disproportionality Analysis from Vigibase and AERS Databases

(173) Teriparatide and Potential Risk of Multiple Myeloma

(236) Signal Detection for Adverse Events of Dapagliflozin Using the Korea Adverse Event Reporting System Database

(316) Risk of Retinal Vein Occlusion in Colorectal Cancer Patients Using Anti-Vascular Endothelial Growth Factor: A Population-Based Cohort Study

(210) Trends in FDA Post-Marketing Commitments and Requirements for Newly Approved Drugs, 2016-2021

(171) Unintended Impact of Medicines Regulatory Interventions: A Systematic Review Focusing on Data and Methods

(230) Tumor Lysis Syndrome Associated with Bruton's Tyrosine Kinase Inhibitor: A Disproportionality Analysis in a Spontaneous Reporting Database

(235) What Makes EU Regulators Want to Communicate About Drug Safety Signals: Results from An Online Survey Study

(325) Use of Histamine-2 Receptor Antagonists and Risk of Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis of Observational Studies